Oral alpha-cyclodextrin reverses cholesterol-crystal-induced retinal pathology in a rodent model of type 2 diabetes

Today’s cyclodextrin a study showing how alpha-CD treatment could be used in type-2 diabetes patients.
Cholesterol crystals were eliminated from the retinas of diabetic mice after oral alpha-cyclodextrin treatment. These findings demonstrate that T2D is associated with cholesterol crystal-induced retinal pathology that is improved using oral alpha-cyclodextrin. Improvements were observed in inflammation, neural function and visual response.

Oral alpha-cyclodextrin reverses cholesterol-crystal-induced retinal pathology in a rodent model of type 2 diabetes (T2D). | IOVS | ARVO Journals

New Captisol (Ligand Pharmaceuticals) enabled API on the market!

Today’s cyclodextrin:

Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol®, a Ligand technology.

About perampanel (Fycompa®)
Perampanel is a first-in-class anti-epileptic agent (AED) discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is currently approved in more than 75 countries and territories, including Japan, China, and other countries in Europe and Asia, as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. In addition, perampanel has been approved in more than 70 countries, including Japan, Europe, and Asia, for treatment as an adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In Japan and China, perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older. In Europe, the approved age range is 4 years of age and older for the adjunctive treatment of partial-onset seizures (with or without secondarily generalized seizures) and 7 years of age and older for the treatment as an adjunctive therapy for primary generalized tonic-clonic seizure. A tablet, fine granule formulation, and injection formulation have been approved in Japan. An oral suspension formulation and tablet have been approved in Europe and China. In January 2023, the commercial rights in the United States were transferred to Catalyst Pharmaceuticals, Inc.

Stable, liquid pharmaceutical compositions comprising Melphalan

The cyclodextrin-enabled formulation of melphalan is an excellent example of how outdated excipients could be replaced with safer and more effective cyclodextrins to create patient-friendly and superior drug products!
Espacenet – Stable, liquid pharmaceutical compositions comprising melphalan
here you can find similar examples: Formulation development – www.carbohydesolutions.com

Functionalization of cotton nonwoven with cyclodextrin/lawsone inclusion complex nanofibrous coating for antibacterial wound dressing

Today’s cyclodextrin is a new type of wound dressing developed at Cornell University by Tamer Uyar‘s team.

Bioactive compounds like lawsone offer dual benefits of wound healing and infection prevention, however, their limited solubility and viability hinder their applications. To address this, Hydroxypropyl-beta-cyclodextrin (HP-β-CD) and Hydroxypropyl-gamma-cyclodextrin (HP-γ-CD) were employed.

Electrospinning yielded smooth and uniform nanofibers with an average diameter of ∼300–700 nm. The nanofibers exhibited ∼100 % loading efficiency of lawsone and its rapid release upon dissolution.

Notably, antibacterial assays demonstrated the complete elimination of Escherichia coli and Staphylococcus aureus colonies. The CD/lawsone nanofibers also showed suitable antioxidant activity ranging from 50% to 70%.

Functionalization of cotton nonwoven with cyclodextrin/lawsone inclusion complex nanofibrous coating for antibacterial wound dressing – ScienceDirect

Comparative investigation of pulmonary vasodilating effects of inhaled Nitric Oxide (NO) gas therapy and inhalation of SIN-1, a new drug formulation containing an NO-donor metabolite

Today’s cyclodextrin is a nice collaborative formulation and in vivo (porcine) study between Semmelweis University and Cyclolab R&D Ltd.
In the project, the hemodynamic effect of inhalative SIN-1a (the unstable active metabolite of molsidomine, stabilized by cyclodextrine) was studied. The pulmonary vasodilator effect of SIN-1 was dose dependent, and in case of larger dose it was comparable to that of iNO. However, the vasodilatory effects of SIN-1 inhalation was not limited to the pulmonary circulation, a significant and dose-dependent systemic vasodilation could also be documented.
My only regret here is not all contributors met the authors’ list finally.

Comparative investigation of pulmonary vasodilating effects of inhaled Nitric Oxide (NO) gas therapy and inhalation of SIN-1, a new drug formulation containing an NO-donor metabolite | European Heart Journal | Oxford Academic (oup.com)

Cyclodextrin-Enabled Enantioselective Complexation Study of Cathinone Analogs

We have a nice read to propose for the week-started coffee, the most recent work of Szabolcs Béni from our advisory board and András DohárszkyFejős IdaEszter Kalydi and Gergely Völgyi.
A comprehensive investigation of the stability of cathinone derivatives and their cyclodextrin complexes.

Molecules | Free Full-Text | Cyclodextrin-Enabled Enantioselective Complexation Study of Cathinone Analogs (mdpi.com)

Towards an efficient method for removing PFAS from water

Today’s cyclodextrin is highlighting a wonderful and important achievement from Aalborg University by Mads Koustrup Jørgensen and Thorbjørn Terndrup Nielsen, who are combining cyclodextrin chemistry and membrane technology in a new filtration project. They hope to present an effective and economically sustainable method for removing PFAS from our drinking water within a few years.

“In short, by rinsing a membrane in a specific alcohol solution of cyclodextrins, we can make the cyclodextrins bind to the membrane surface, making it functional for PFAS absorption without the need for complex chemistry,” says Mads Koustrup Jørgensen.

Learn more about the project here: Towards an efficient method for removing PFAS from water – Aalborg University (aau.dk)

This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin

today’s cyclodextrin:
is a fascinating and one-of-a-kind drug delivery vehicle. Nicole Steinmetz and Ivonne González-Gamboa created nanoparticles based on tobamovirus, to which they covalently attached beta-cyclodextrin that can non-covalently bind one or more active ingredients.
Such chemistry is not easy; you can learn more about it here: Custom synthesis of cyclodextrins – www.carbohydesolutions.com

METHODS AND COMPOSITIONS COMPRISING TOBACCO MILD GREEN MOSAIC VIRUS (TMGMV)

Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes

We have seen many applications for using cyclodextrin as active ingredients, yet diabetes has not been on the list yet.
Until now.
Alessia Fornoni and Merscher Sandra shared a concept for reducing lipid content in a cell or plasma membrane of a cell in a patient suffering from diabetes to redistribute or reduce cellular cholesterol accumulation.

US20230338412 METHOD OF USING CYCLODEXTRIN (wipo.int)

Acute Effects of 30 g Cyclodextrin Intake during CrossFit® Training on Performance and Fatigue

Today’s cyclodextrin:
Ready for some weekend workout? Have you planned to take some cyclodextrin afterward?
This study by Ismael Martínez Guardado and colleagues looks into the effect of taking 30 g cyclodextrin (Cluster Dextrin® – which is not clear to me what kind of cyclodextrin is, if any) during CrossFit Training on Performance and Fatigue. Although some differences were found, supplementation with 30 g of cyclodextrin did not have any metabolic or performance effects in CrossFit tests.

JFMK | Free Full-Text | Acute Effects of 30 g Cyclodextrin Intake during CrossFit® Training on Performance and Fatigue (mdpi.com)